Joule Is Poised For Significant Progress in 2015

Joule Is Poised For Significant Progress in 2015

February 23, 2015

Reaches major milestones in 2014 to enable broad industrialization of its carbon-neutral transportation fuels

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

February 17, 2015

Positive early clinical results in three distinct investigational medicines and a strong financial position support advancement of the Agios portfolio into late stage development

Avedro Announces Date for FDA Advisory Committee Meeting

Avedro Announces Date for FDA Advisory Committee Meeting

February 17, 2015

Committee to Review Avedro’s NDA for Riboflavin Ophthalmic Solutions with UVA Irradiation on February 24, 2015

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

February 10, 2015

- Abstract at AACR Translation of the Cancer Genome meeting describes novel approach to discovery of gene control biomarkers -

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

February 4, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert's product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities.

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

February 3, 2015

Collaboration Leverages T2 Biosystems' Proprietary T2MR(R) Technology and Canon's Collective Expertise to Enable Improved Diagnostics

Symbiota Names Global Crop Protection Expert Peter Innes, Ph.D. to Board of Directors

Symbiota Names Global Crop Protection Expert Peter Innes, Ph.D. to Board of Directors

February 3, 2015

CAMBRIDGE, Mass., Feb. 3, 2015 /PRNewswire/ -- Symbiota™, pioneer of plant microbiome solutions that naturally promote crop health and improve agricultural production, today announced the addition of Peter Innes, Ph.D. to its board of directors.

Moderna and Institut Pasteur Sign Strategic Research Collaboration

Moderna and Institut Pasteur Sign Strategic Research Collaboration

February 3, 2015

Research partnership will advance the development of mRNA vaccines and passive immunity therapies for infectious diseases

Acceleron Pharma to Present at Upcoming Investor Conferences in February

Acceleron Pharma to Present at Upcoming Investor Conferences in February

January 28, 2015

CAMBRIDGE, Mass., Jan 28, 2015 (BUSINESS WIRE) -- Acceleron Pharma Inc. XLRN, -1.52% a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in the following upcoming investor conferences.

Event: Canaccord Genuity Rare Disease, Biopharma One-on-One Day
Date / Time: Tuesday, February 3, 2015
Location: Omni Berkshire Place Hotel, New York, N.Y.

Event: Leerink Global Healthcare Conference

BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association

BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association

January 22, 2015

− Prof. Robert S. Langer provides insight on potential for application of nanomedicine in broad therapeutic areas −